Acasti Pharma Inc reports results for the quarter ended in March - Earnings Summary

Grace Therapeutics

21/06/2024 15:19

* Acasti Pharma Inc  ACST.OQ  reported a quarterly adjusted
loss
of 18 cents​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of $-3.90.  The lone analyst forecast for the quarter was for a
loss of 47 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Acasti Pharma Inc's reported EPS for the quarter was a
loss
of 26 cents​.
    * The company reported a quarterly loss of C$3.17 million.
    * Acasti Pharma Inc shares had fallen by 8.0% this
quarter and
gained 9.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Acasti Pharma Inc
is $6.00 
This summary was machine generated from LSEG data June 21 at
02:19 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jan. 1 0001       -0.47          -0.18          Beat
 Dec. 31 2023                     -0.30          
                                  -0.27          
                                  -0.46